Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ethical issues in psychopharmacology.

Literature DB >> 16816041

Ethical issues in psychopharmacology.

Abstract

The marketing of selective serotonin reuptake inhibitors in the psychopharmacological industry presents a serious moral problem for the corporate model of medicine. In this paper I examine ethical issues relating to the efficacy and safety of these drugs. Pharmaceutical companies have a moral obligation to disclose all information in their possession bearing on the true risks and benefits of their drugs. Only then can patients make fully informed decisions about their treatment.

Entities: Species

Mesh：

Substances：

Year: 2006 PMID： 16816041 PMCID： PMC2564489 DOI： 10.1136/jme.2005.013185

Source DB: PubMed Journal: J Med Ethics ISSN： 0306-6800 Impact factor: 2.903

28 in total

1. Uneasy alliance--clinical investigators and the pharmaceutical industry.

Authors: T Bodenheimer
Journal: N Engl J Med Date: 2000-05-18 Impact factor: 91.245

Review 2. Suicide in the course of the treatment of depression.

Authors: D Healy; C Langmaak; M Savage
Journal: J Psychopharmacol Date: 1999 Impact factor: 4.153

3. Interface between authorship, industry and science in the domain of therapeutics.

Authors: David Healy; Dinah Cattell
Journal: Br J Psychiatry Date: 2003-07 Impact factor: 9.319

Review 4. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials.

Authors: Dean Fergusson; Steve Doucette; Kathleen Cranley Glass; Stan Shapiro; David Healy; Paul Hebert; Brian Hutton
Journal: BMJ Date: 2005-02-19

Review 5. Efficacy of antidepressants in adults.

Authors: Joanna Moncrieff; Irving Kirsch
Journal: BMJ Date: 2005-07-16

6. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review.

Authors: David Gunnell; Julia Saperia; Deborah Ashby
Journal: BMJ Date: 2005-02-19

7. Modified amine hypothesis for the aetiology of affective illness.

Authors:
Journal: Lancet Date: 1972-09-16 Impact factor: 79.321

8. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors.

Authors: H Nordeng; R Lindemann; K V Perminov; A Reikvam
Journal: Acta Paediatr Date: 2001-03 Impact factor: 2.299

9. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.

Authors: A Khan; H A Warner; W A Brown
Journal: Arch Gen Psychiatry Date: 2000-04

Review 10. Suicide attempts in clinical trials with paroxetine randomised against placebo.

Authors: Ivar Aursnes; Ingunn Fride Tvete; Jorund Gaasemyr; Bent Natvig
Journal: BMC Med Date: 2005-08-22 Impact factor: 8.775

3 in total

1. Psychiatry in the 21st century: the glass is half full.

Authors: Jürgen Unützer
Journal: World Psychiatry Date: 2022-10 Impact factor: 79.683

2. How psychiatry journals support the unbiased translation of clinical research. A cross-sectional study of editorial policies.

Authors: Hannes Knüppel; Courtney Metz; Joerg J Meerpohl; Daniel Strech
Journal: PLoS One Date: 2013-10-16 Impact factor: 3.240

3. Presentation of benefits and harms of antidepressants on websites: A cross-sectional study.

Authors: Maryanne Demasi; Peter C Gøtzsche
Journal: Int J Risk Saf Med Date: 2020

3 in total